Trxade Health Inc is a healthcare technology company focused on improving the accessibility and affordability of prescription medications
The company operates a digital platform that connects various stakeholders in the pharmaceutical supply chain, including independent pharmacies, healthcare practitioners, and patients. Through its innovative services, Trxade Health enables pharmacies to source medications more efficiently, enhances transparency in pricing, and supports the delivery of healthcare solutions that aim to reduce the overall cost burden on patients. The firm is committed to leveraging technology to foster a more integrated and consumer-friendly healthcare marketplace.
Shares of Mesoblast Limited (NASDAQMESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients. Mesoblast shares jumped 13.4% to $2.4399 on Monday.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Wednesday. The Dow traded up 0.20% to 38,662.69 while the NASDAQ rose 0.64% to 16,041.08. The S&P 500 also rose, gaining, 0.53% to 5,105.72.
TRxADE Health said the special dividend is being paid using a portion of the proceeds from the closing of the recently announced sale of the company's web-based market platform assets and is payable to stockholders of record as of March 18 with the dividend being paid on or about March 22.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Wednesday. The Dow traded up 0.62% to 38,825.33 while the NASDAQ rose 0.81% to 16,069.34. The S&P 500 also rose, gaining, 0.80% to 5,119.15.
